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It has become apparent that the axillary apocrine sweat gland in man is under
endocrine control, since its very development and function heralds puberty (1).
Furthermore the hormonal changes associated with pregnancy or the menopause
may produce striking functional and histologic changes (2). Unfortunately
nothing is known regarding the details of such hormonal control. We were led
to the present study by a realization of the need for such knowledge as a basis
for rational therapy of certain diseases of the apocrine gland. Our studies con-
sisted of a histologic investigation of the effect of a wide variety of hormones
on normal human axillary skin. Only clinically feasible dosages were employed
and the period of topical as well as systemic treatment was kept constant at
three weeks.
METHOD
Table I outlines the dosage schedules and the routes of administration for
the various hormones studied. Each hormone, combination of hormones, or
dosage schedule was administered to normal healthy adult male volunteers
between the age of 20 and 40 years. As indicated, the topical estrogens and
androgens were studied on eight additional men over 60 years of age. At the
end of the three weeks of topical therapy, the treated and untreated (control)
axillae were compared clinically and biopsy specimens obtained from each axil-
lary vault. The subjects receiving systemic therapy had biopsies prior to and
at the end of the three week period. All of the biopsies were serially sectioned
and stained with hematoxylin and eosin. A total of 170 biopsies were taken with
an average of 300 serial sections per biopsy. The use of large deep surgical
excision biopsies and serial sections minimized errors of interpretation which
commonly arise from a failure to see a completely representative cross section
of the apocrine glands.
RESULTS AND DISCUSSION
Careful study both clinically and histologically did not reveal any significant
changes between the treated and untreated axillary skin. The apocrine sweat
glands, in common with the hair, sebaceous glands, eccrine glands, epidermis,
and corium, appeared unaffected by either the three week course of topical or
systemic hormonal therapy.
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TABLE I
A. Topical Therapy
Hormone Vehicle Concentrations Application No. of Subjects
1. Ethinyl
estradiol
95% ethyl al-
cohol
1:100,000*
1:20,000*
1:10,000*
1:1,000*
1:100
1:10
Wet gauze. 30 mm. daily
for 3 weeks. Control
axilla; ethyl alcohol
only
2
2
2
2
1
1
2. Testosterone
(base)
95% ethyl al-
cohol
1:100,000*
1:20,000*
1:10,000*
1:1,000*
1:100
1:10
Wet gauze. 30 mm. daily
for 3 weeks. Control ax-
illa; ethyl alcohol only
2
2
2
2
1
1
3. Progesterone 95% ethyl a!-
cobol
1:100,000
1:10,000
1:1,000
1:100
1:10
Wet gauze. 30 mm. daily
for 3 weeks. Control
axilla; ethyl alcohol
only
2
1
1
1
1
4. Tri-iodo-
thyronine
Vanishing
cream base
1:1,000
1:100
Massage twice daily for 3
weeks. Control axillae
untreated
4
4
B. Systemic Therapy
Hormone Dose Route Frequency No. of Subjects
1. Ethinyl es-
tradiol
(Estinyl,
Schering)
2. Methyl tes-
tosterone
(Metandren
Linguets,
Ciba)
3. Progesterone
(Progester-
one Lingu-
osorbs,
Ayerst
McKenna
Harrison)
4. Thyroid
(Thyroid
tablet,
Armour)
0.1 mgm.
0.2 mgm.
20 mgm.
50 mgm.
60 mgm.
Oral
Oral
Under lip
Under lip
Oral
Daily for 3 weeks
Daily for 3 weeks
Daily for 3 weeks
Daily for 3 weeks
Daily for 3 weeks
4
4
4
4
4
EFFECT OF HORMONES ON HUMAN SKIN 129
TABLE I—Continued
B. Systemic Therapy (Continued)
Hormone Dose Route Frequency No. of Subjects
5. Ethinyl es- 0.1 mgm. Oral Daily for 3 weeks 4
tradiol 20 mgm. Under lip
and
Methyl
testos-
terone
6. Ethinyl es- 0.1 mgm. Oral Daily for 3 weeks 4
tradiol 50 mgm. Under lip
and Pro-
gesterone
7. Ethinyl es- 0.1 mgm. Oral Daily for 3 weeks 4
tradiol 20 mgm. Under lip
and 50 mgm.
Methyl
testos-
terone and
Proges-
terone
8. Methyl 20 mgm. Under lip Daily for 3 weeks 4
testos- 50 mgm.
terone and
Proges-
terone
9. Pituitary 2 cc. (16 rat I.M. Daily for 3 weeks 4
growth units)
hormone
(Antuitrin
growth,
Parke
Davis)
10. Prolactin 1 cc. (200 I.U.) I.M. Daily for 3 weeks 4
(Luteotro-
phin,
Squibb)
11. Pituitary 2 cc. (30 syn- I.M. Daily for 3 weeks 4
and cho- ergy rat
rionic units)
gonado-
tropins
(Synapoi-
din, Parke
Davis &
Co.)
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TABLE I—(Concluded)
B. Systemic Therapy (Concluded)
Hormone Dose Route Frequency No. of Subjects
12. Chorionic 1 cc. (1,000 I.M. Daily for 3 weeks 4
gonado- units)
tropin
(Antuitrin
S, Parke
Davis)
* Each of these concentrations was also tested on a subject over 60 years of age.
One striking clinical change did however occur. All the subjects receiving
progesterone systemically, either alone or in association with ethinyl estradiol or
testosterone, noted generalized hyperidrosis. This appeared after several days
of treatment and persisted until treatment was stopped. This finding sheds light
on the etiology of the hyperidrosis which commonly occurs in pregnancy and at
the menopause. It would seem that high levels of progesterone have a central
stimulant effect on the regulatory neural control centers for the eccrine sweat
gland. This observation deserves further study.
Gynecomastia developed in two of the subjects receiving ethinyl estradiol.
Interestingly, both of these men had experienced temporary gynecomastia
previously. Alter cessation of the hormonal therapy the breast changes gradually
underwent involution.
Although the role of hormones in the control of the apocrine sweat gland has
not been previously studied, there are many reports in the literature on the
effect of hormones on the skin (3). In animals dramatic changes have been ob-
served in the growth of the sebaceous gland which we have been unable to
duplicate in man. Species differences, but more particularly dose differences,
probably account for this divergence of results. In man, the only dramatic cu-
taneous changes seen have occurred as a result of long term high dosage hor-
monal treatment employed, as for example, in the control of carcinoma of the
breast (4, 5). The current study indicates that at present the physician has no
reason to believe that hormonal therapy in a clinically safe dose level produces
significant growth changes in the skin.
SUMMARY
A wide variety of hormones, applied topically, as well as given systemically,
proved to be without effect on the normal axillary skin and apocrine sweat gland
in man.
Progesterone caused generalized hyperidrosis when given sublingually in a
daily dosage of 50 mg.
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